Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
Status:
RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, open-label, exploratory study to determine the safety, tolerability, feasibility, and preliminary anti-tumor activity of anti-CD19-CAR-T cells in subjects with relapsed/refractory (r/r) B-cell malignancies.
This study plans to enroll patients with relapsed/refractory CD19-positive B-cell malignancies, who will receive a single infusion of anti-CD19-CAR-T cells after screening, PBMC collection, and lymphodepleting chemotherapy.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Shanghai First Song Biotechnology Co., LTD
Collaborator:
The First Affiliated Hospital of Anhui Medical University